Cumberland Pharmaceuticals (CPIX) vs PDS Biotechnology (PDSB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cumberland Pharmaceuticals (CPIX) has outperformed PDS Biotechnology (PDSB) over the past year, gaining 98.0% versus a gain of 40.0%. Over five years, CPIX leads with a +156.6% price change compared with -88.8% for PDSB. Cumberland Pharmaceuticals is the larger company by market cap ($105.3 million vs $100.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CPIX | PDSB |
|---|---|---|
| Share price | $7.03 | $1.38 |
| Market cap | $105.33M | $100.01M |
| 1-day change | +0.72% | +35.29% |
| YTD return | +76.63% | +79.22% |
| 1-year return | +98.03% | +39.96% |
| 5-year return | +156.57% | -88.81% |
| Forward P/E | 50.21 | — |
| EPS (TTM) | $-0.62 | $-0.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.28 | $1.55 |
| 52-week low | $1.85 | $0.195 |
| Distance from 52-week high | -24.25% | -10.97% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +262.32% |
| Average volume | 88.03K | 23.24M |
| Shares outstanding | 14.98M | 72.47M |
| Employees | 88 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CPIX has outperformed PDSB by 58.1 percentage points over the past year.
About Cumberland Pharmaceuticals
CPIX stock →Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H.
Health Care · Biotechnology: Pharmaceutical Preparations · 88 employees
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
CPIX vs PDSB FAQ
Which is bigger, Cumberland Pharmaceuticals or PDS Biotechnology?
Cumberland Pharmaceuticals (CPIX) is larger, with a market capitalization of $105.33M compared with $100.01M for PDS Biotechnology (PDSB).
Which stock has performed better over the past year, CPIX or PDSB?
CPIX returned +98.03% over the past 12 months, compared with +39.96% for PDSB (price return, excluding dividends). Past performance does not predict future results.
Are Cumberland Pharmaceuticals and PDS Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.